Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (311)	7/30/1998 1:03:00 PM
From: MCorbley	Read Replies (2) \| Respond to of 410

Re: Seprafilm. I have never felt that long term studies of cost effectiveness are going to be the driving force behind Seprafilm. Rather, I believe that Seprafilm or a similar product would simply become a standard of high quality healthcare. An analogy would be pain medication. Hospitals give all kinds of pain medication nowadays to make patients more comfortable. I don't think pain medication is cost-effective. It has simply become the standard of care. And my understanding is that the rate of surgical adhesions is much, much higher than 2.5%, although most of those do not require another surgery. Simply opening the abdomen and touching anything inside (with a gloved hand, for example) seems to traumatize the tissue in such a way that adhesions can form.